Supplementary MaterialsFigure 1source data 1: Gene specificity and context-dependency of coregulator contribution to androgen regulation of AR target gene expression. are identified in ARBSs of coregulator-dependent AR target gene sets using Cistrome project tools. elife-28482-fig2-data1.docx (43K) DOI:?10.7554/eLife.28482.010 Figure 2source data 2: Overview of the number of Ingenuity Pathway Analysis categories that associate with individual coregulator-dependent AR target gene signatures. elife-28482-fig2-data2.docx (32K) DOI:?10.7554/eLife.28482.011 Figure 2source data 3: Overview of transcription factor (TF) binding sites identified in ARBSs present in 452 AR target genes. Overview of transcription factor (TF) binding sites identified in ARBSs present in 452 AR target genes. Left to right: Column 1: TF binding sites identified in ARBSs in the overarching 452 AR target gene signature. Columns 2C18: TF binding sites identified in ARBSs in AR target gene sets that depend on the 17 coregulators shown. Blue, statistically significantly enrichment of the TF binding sites and corresponding p-value; none, no statistically significant TF binding site enrichment. elife-28482-fig2-data3.xlsx (44K) DOI:?10.7554/eLife.28482.012 Figure 5source data 1: PGAM5 peptides identified after IP-mass spectrometry. elife-28482-fig5-data1.docx (13K) DOI:?10.7554/eLife.28482.016 Figure 6source data 1: Summary of p-values for data presented in Figure 6. For panels A, C, D, and E, p-values were derived using welch two sample t-test. Values are compared to those obtained from the control siRNA group with changes considered significant at p 0.05. For panel B, p-values are derived using paired t-test. The fold change in values obtained after R1881 treatment is calculated for each siRNA group and values for specific Arranon cost siRNA groups are compared to those derived from the control siRNA group. Changes are considered significant at p 0.05. elife-28482-fig6-data1.docx (15K) DOI:?10.7554/eLife.28482.018 Supplementary file 1: Design of oligoarray, overview of AR target genes studied, and overview of coregulators considered for analysis. (A) Overview of genes included in custom Agilent oligoarray Rows, categories of genes included on 8 15K custom Agilent oligoarray. Columns, Number of genes identified for inclusion on the array, and number of genes for which Agilent catalogue probes were available for inclusion. CSF2 (B) Overview of 452 AR target gene signature Gene name, HUGO gene symbol; FC, fold change (C) Overview of coregulators considered, prioritized and withheld for analysis A PudMed search for papers that contain the terms AR and CaP in their title and/or abstract was performed. Abstracts fulfilling these criteria were screened for reference to coregulator function, and if so, full-length papers were reviewed individually to verify description of a AR-associated coregulator. Left to right: Column 1: 181 coregulators for which literature search was done. Column 2: 51 coregulators for which differential protein expression has been reported in CaP when compared to benign prostate (yes entries). Column 3: 22 coregulators for which differential expression in CaP correlated with aggressive disease, and were analyzed in Figures 4C6 (yes entries). Column 4: 18 coregulators for which siRNA-mediated silencing did not affect AR expression, CaP cell morphology or CaP cell survival and were included in final analyses (yes entries). elife-28482-supp1.docx (59K) DOI:?10.7554/eLife.28482.019 Supplementary file 2: Characterization of 452 AR target gene signature (A) Androgen regulation of AR target gene Arranon cost expression in VCaP cells VCaP cells were Arranon cost seeded in medium supplemented with charcoal-stripped FBS (CSS). 2 days later, medium was changed and cells were treated with 5 nm R1881 or ethanol vehicle for 48 hr. Cells were harvested and AR target gene expression was evaluated using real-time RT-PCR. Target gene mRNA levels were normalized with the values obtained from GAPDH expression and are.